Oxomemazine API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Oxomemazine API 3689-50-7?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Oxomemazine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Oxomemazine
- Synonyms:
- Cas Number:
- 3689-50-7
- DrugBank number:
- DB13820
- Unique Ingredient Identifier:
- 305MB38V1C
General Description:
Oxomemazine is a chemical compound identified by the CAS number 3689-50-7. It is known for its distinct pharmacological properties and applications.
Classification:
Oxomemazine belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring, classified under the direct parent group Phenothiazines. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Benzothiazines class, specifically within the Phenothiazines subclass.
Categories:
Oxomemazine is categorized under the following therapeutic classes: Antihistamines for Systemic Use, Heterocyclic Compounds, Fused-Ring, Phenothiazine Derivatives, Sulfur Compounds. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Oxomemazine is a type of Anti-allergy agents
Anti-allergy agents, also known as antihistamines, are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of allergies. These substances work by blocking the effects of histamine, a chemical released by the body's immune system during an allergic reaction.
Antihistamines act on histamine receptors, preventing them from binding to target cells and thus inhibiting the release of allergic symptoms such as itching, sneezing, and watery eyes. These APIs can be classified into two generations based on their characteristics.
First-generation antihistamines, such as diphenhydramine and chlorpheniramine, are known for their sedative properties due to their ability to cross the blood-brain barrier. Although effective in relieving allergy symptoms, they often cause drowsiness, impairing daily activities.
Second-generation antihistamines, including cetirizine and loratadine, were developed to address the sedative side effects of their predecessors. These newer APIs have a higher selectivity for peripheral histamine receptors and a reduced ability to penetrate the central nervous system, resulting in reduced sedation.
Anti-allergy APIs are available in various formulations, including oral tablets, liquids, nasal sprays, and eye drops. They are widely used to alleviate allergic reactions caused by pollen, dust mites, pet dander, and other environmental allergens. These agents provide relief from symptoms such as itching, runny nose, congestion, and hives.
In summary, anti-allergy agents are a vital category of APIs used to manage allergic reactions. They block the effects of histamine, providing relief from allergy symptoms. The development of second-generation antihistamines has significantly reduced sedative side effects, improving patient comfort. These APIs are available in different formulations, catering to the diverse needs of allergy sufferers.
